Congress Repeals Medicare Therapy Caps and Lifts Limits on Speech-Generating Devices

Congress has permanently repealed Medicare Part B therapy caps and permanently extended the Steve Gleason Enduring Voices Act, which authorizes the purchase of speech-generating devices (SGDs). The measures were included in a continuing resolution passed yesterday that funds the federal government for the next two years. Medicare Part B Therapy Cap The resolution permanently eliminates the hard cap on how much outpatient speech-language, occupational and physical therapy each Medicare beneficiary is allowed per year. Congress has allowed an exceptions process in most of the past 20 years, but this permanent fix repeals the cap and replaces it with a more flexible targeted medical review threshold of $3,000. Even with a threshold of $3,000, clinicians must use the KX modifier—which indicates ongoing medical necessity—when a patient’s therapy services exceed $2,010 (the level of the previous cap). If an SLP meets certain billing criteria (yet to be announced), the clinician may be required to submit medical records for some of the claims above the $3,000 threshold for review. ASHA anticipates that the targeting criteria and review process will be similar or identical to the most recent therapy caps exceptions process. We will share the details when they become available. Steve Gleason Enduring Voices Act The resolution also requires Medicare to cover the purchase of SGDs permanently. Most of the people who use SGDs have neurodegenerative diseases such as amyot...
Source: American Speech-Language-Hearing Association (ASHA) Press Releases - Category: Speech-Language Pathology Authors: Tags: Advocacy Audiology Speech-Language Pathology Augmentative Alternative Communication Technology Source Type: blogs

Related Links:

Publication date: Available online 30 June 2018Source: PM&RAuthor(s): Richard D. Zorowitz, David N. Alexander, Andrea E. Formella, Fred Ledon, Charles Davis, Joao SiffertAbstractBackgroundDextromethorphan (DM)/quinidine (Q) was approved for pseudobulbar affect (PBA) treatment based upon efficacy and safety trials in patients with PBA secondary to amyotrophic lateral sclerosis or multiple sclerosis. The PRISM II trial evaluated DM/Q as PBA treatment in patients with stroke, dementia or traumatic brain injury.ObjectiveTo report results from the stroke cohort of PRISM II, including the Stroke Impact Scale (SIS).DesignOpen-lab...
Source: PMandR - Category: Rehabilitation Source Type: research
CONCLUSION: Cytokines get upregulated during neurodegenerative diseases as a result of which inflammatory responses are initiated in the brain. Curcumin is reported to have anti-inflammatory properties and thereby its supplementation may help in reducing the inflammation. Future researches on this area will further explain the mode of action of curcumin in alleviating neuroinflammation. PMID: 29972106 [PubMed - as supplied by publisher]
Source: Recent Patents on Inflammation and Allergy Drug Discovery - Category: Allergy & Immunology Tags: Recent Pat Inflamm Allergy Drug Discov Source Type: research
Publication date: Available online 30 June 2018Source: PM&RAuthor(s): Richard D. Zorowitz, David N. Alexander, Andrea E. Formella, Fred Ledon, Charles Davis, Joao SiffertAbstractBackgroundDextromethorphan (DM)/quinidine (Q) was approved for pseudobulbar affect (PBA) treatment based upon efficacy and safety trials in patients with PBA secondary to amyotrophic lateral sclerosis or multiple sclerosis. The PRISM II trial evaluated DM/Q as PBA treatment in patients with stroke, dementia or traumatic brain injury.ObjectiveTo report results from the stroke cohort of PRISM II, including the Stroke Impact Scale (SIS).DesignOpen-lab...
Source: PMandR - Category: Rehabilitation Source Type: research
Abstract Neurotoxic metals have been implicated in the pathogenesis of multiple sclerosis, neurodegenerative disorders and brain tumours but studies of the location of heavy metals in human brains are rare. In a man who injected himself with metallic mercury the cellular location of mercury in his brain was studied after 5 months of continuous exposure to inorganic mercury arising from metallic mercury deposits in his organs. Paraffin sections from the primary motor and sensory cortices and the locus ceruleus in the pons were stained with autometallography to detect inorganic mercury and combined with glial f...
Source: Biometals - Category: Biochemistry Authors: Tags: Biometals Source Type: research
CONCLUSION: In this reverence, the present study reviews the current consideration of the mode of action and the future prediction concerning the use of novel compounds isolated from arthropods and other venomous animals in the treatment of major neurodegenerative diseases such as Parkinson disease, Alzheimer disease, Multiple Sclerosis, Epilepsy and Amyotrophic Lateral Sclerosis. PMID: 29921193 [PubMed - as supplied by publisher]
Source: Protein and Peptide Letters - Category: Biochemistry Authors: Tags: Protein Pept Lett Source Type: research
AbstractNeurological diseases, such as Parkinson ’s disease, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS) and multiple sclerosis, are often associated with functional gastrointestinal disorders. These gastrointestinal disturbances may occur at all stages of the neurodegenerative diseases, to such an extent that they are now consi dered an integral part of their clinical picture. Several lines of evidence support the contention that, in central neurodegenerative diseases, changes in gut microbiota and enteric neuro-immune system alterations could contribute to gastrointesinal dysfuncti...
Source: Acta Neuropathologica - Category: Neurology Source Type: research
Semin Neurol 2018; 38: 176-181 DOI: 10.1055/s-0038-1649338“Stem cell tourism” is defined as the unethical practice of offering unproven cellular preparations to patients suffering from various medical conditions. This phenomenon is rising in the field of neurology as patients are requesting information and opportunities for treatment with stem cells for incurable conditions such as multiple sclerosis and amyotrophic lateral sclerosis, despite their clinical research and experimental designation. Here, we review the recent trends in “stem cell tourism” in both the United States and abroad, and discus...
Source: Seminars in Neurology - Category: Neurology Authors: Tags: Review Article Source Type: research
CONCLUSION: Findings from a number of clinical and experimental paradigms suggest spinal cord OPCs/oligodendrocytes are a potential therapeutic target for the control of neuroinflammation. PMID: 29788868 [PubMed - as supplied by publisher]
Source: Current Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Med Chem Source Type: research
zon E Abstract Neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and multiple sclerosis are characterized by a chronic and selective process of neuronal cell death. Although the causes of neurodegenerative diseases remain still unknown, it is now a well-established idea that more factors, such as genetic, endogenous, and environmental, are involved. Among environmental causes, the accumulation of mercury, a heavy metal considered a toxic agent, was largely studied as a probable factor involved in neurodegenerative disease course. Mercury exists in three mai...
Source: Biological Trace Element Research - Category: Biology Authors: Tags: Biol Trace Elem Res Source Type: research
FDA is cracking down on stem cell clinics that market unapproved products and don't meet good manufacturing practice requirements. On behalf of the agency, the Department of Justice filed two complaints in federal court this week seeking permanent injunctions against a Florida-based clinic and a California-based clinic.  “Cell-based regenerative medicine holds significant medical opportunity, but we’ve also seen some bad actors leverage the scientific promise of this field to peddle unapproved treatments that put patients’ health at risk. In some instances, patients have suffered serious and per...
Source: MDDI - Category: Medical Devices Authors: Tags: Regulatory and Compliance Source Type: news
More News: ALS | Audiology | Brain | Education | Funding | Government | Graduation | Health Insurance | Health Management | Hospitals | Insurance | Medical Billing | Medicare | Multiple Sclerosis | National Health Service (NHS) | Neurology | Nurses | Nursing | Occupational Health | Pathology | Physical Therapy | Politics | Speech Therapy | Speech-Language Pathology | UK Health | Universities & Medical Training